Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer

Ir J Med Sci. 2023 Dec;192(6):2681-2687. doi: 10.1007/s11845-023-03448-w. Epub 2023 Jul 6.

Abstract

Purpose: To investigate the value of serum free prostate-specific antigen density (fPSAD) in the diagnosis of prostate cancer (PCa).

Methods: The data of 558 patients who underwent transrectal ultrasound-guided prostate biopsy were retrospectively analyzed. According to the pathological results, the patients were divided into a PCa group and a benign prostatic hyperplasia (BPH) group. Receiver operating characteristic curves were plotted, based on which the sensitivity, specificity, Youden index, concordance, and kappa values of free prostate-specific antigen (fPSA), the free-to-total f/tPSA, prostate-specific antigen density (PSAD), the free-to-total (f/t)/PSAD ratio, and fPSAD were compared. The patients were divided into three groups by PSA levels (PSA < 4 ng/mL, PSA = 4-10 ng/mL, and PSA > 10 ng/mL), into three groups by age (age < 60 year, age = 60-80y, and age > 80 years), and into two groups by prostate volume (PV) (PV ≤ 80 mL and PV > 80 mL) to compare the sensitivity, specificity, and concordance of indicators.

Results: tPSA, PSAD, (f/t)/PSAD, and fPSAD had high accuracy in predicting PCa with AUC values of 0.820, 0.900, 0.846, and 0.867. fPSAD showed lower diagnostic sensitivity but significantly higher specificity and concordance for PCa than tPSA, f/tPSA, (f/t)/PSAD, or PSAD. Thus, fPSAD had the highest accuracy in the diagnosis of PCa. In the groups with different PSA, age, and PV stratification, the concordance of fPSAD was significantly higher (88.61%, 90.74%, and 90.38%) than that of other indicators.

Conclusion: With the optimal cutoff value of 0.062, fPSAD has a higher diagnostic value for PCa than tPSA, f/tPSA, (f/t)/PSAD, and PSAD, and can well predict the risk of PCa, significantly improve the clinical diagnostic rate of PCa, and reduce unnecessary biopsy.

Keywords: Concordance; Diagnosis; Free prostate-specific antigen density; Prostate cancer.

MeSH terms

  • Humans
  • Male
  • Middle Aged
  • Prostate / diagnostic imaging
  • Prostate / pathology
  • Prostate-Specific Antigen
  • Prostatic Hyperplasia* / diagnosis
  • Prostatic Neoplasms* / diagnosis
  • Prostatic Neoplasms* / pathology
  • ROC Curve
  • Retrospective Studies
  • Sensitivity and Specificity

Substances

  • Prostate-Specific Antigen